secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001549595-24-000048
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Therapeutics Q1 FY2024 revenue $16.6M, net loss $41.5M; Gilead collaboration extended
--------------------------------------------------------------------------------

- Revenue $16.6M (up 31% YoY); net loss $41.5M ($0.76/sh) vs $40.7M ($0.75/sh) prior year.
- Cash $254.3M vs $295.3M at Nov 30, 2023; R&D spend $50.0M (up 9% YoY).
- Gilead extended collaboration by 2 years, paying $15M extension fee; total potential milestones up to $1.7B.
- Sanofi extended STAT6 program; Nurix expects to nominate clinical candidate in 12 months.
- FDA lifted partial clinical hold on NX-2127 (BTK degrader) in March 2024; enrollment to reinitiate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000048/0001549595-24-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000048/nrix-20240410.htm
  HTML page:      https://secwatch.observer/filing/0001549595-24-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer